Pα+ Psychedelic Patent Analysis (November 2023)
- General Overview
- Key Terms
- Patent Filings Provide First Look at atai’s NCEs
- Stamets Stacks Up Two New Allowances
- Explore our Psychedelic Patent Trackers
We added 47 PCTs and 26 US patent applications focused on psychedelics to our tracker in the month of November 2023. New entries came from the likes of MindMed, DemeRx, CaaMTech, Mydecine, Enveric, atai, Cybin, and even Paul Stamets.
In November, we also began regularly tracking prosecution status updates for the 800+ US patent applications in our database. As a result, we are now able to provide you with a more granular look at the psychedelic intellectual property landscape as it evolves in the US.
Using the tables below, you can explore applications that were not only published or granted in November, but also those that were allowed, abandoned, rejected, or even instances where applicants filed responses to final and non-final rejections from examiners...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks